Company news
Virax Biolabs Group Limited (NASDAQ:VRAX) news
Virax Biolabs Group Limited news releases on 6ix. Latest, Jul 20, 2026: Alliance Entertainment and Virax Interviews Aired on the RedChip Small Stocks, Big…
Press releases & updates
Alliance Entertainment and Virax Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
July 19, 2026
Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement
July 16, 2026
Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds
July 10, 2026
Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds
July 9, 2026
Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics
July 9, 2026
Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation
June 23, 2026
Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes
May 26, 2026
Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation
March 30, 2026
Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement
December 4, 2025
Virax Biolabs Group Limited Announces $5 Million Private Placement
December 3, 2025
Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders
December 3, 2025
Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes
November 3, 2025
Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September
August 26, 2025
Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy
July 29, 2025
Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency
July 18, 2025
Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes
March 18, 2025
Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting
March 13, 2025
Virax Biolabs to Present at 19th World Immune Regulation Meeting
March 5, 2025
Virax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine Efficacy
February 25, 2025
Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland
December 9, 2024
Virax Biolabs Announces Distribution Agreement with Europa Biosite to Commercialize ImmuneSelect in the United Kingdom and Ireland
October 22, 2024
Virax Biolabs Announces Extension of Existing Exclusive Distribution Agreement to Market Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits with Cosmos Health Inc.
September 15, 2024
Virax Biolabs Announces Distribution Agreement to Commercialize Mpox (formerly Monkeypox) Virus RT-PCR Detection Kits in Europe and the Middle East
August 27, 2024
Virax Biolabs Group Limited Announces $5 Million Registered Direct Offering of Ordinary Shares
August 20, 2024
Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024
April 24, 2024
Virax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients
December 20, 2023
Virax Biolabs Group Limited Announces 1-for-10 Share Consolidation
December 13, 2023
Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar
September 11, 2023
Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum
August 31, 2023
Virax Biolabs Group Announces Establishment of Regional Headquarters at Dubai Science Park
May 3, 2023
Virax Biolabs Group Limited Has Entered into an Agreement for the Distribution of Marburg Virus PCR Testing Kits
April 18, 2023
Virax Biolabs Group Limited Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
March 7, 2023
Virax Biolabs Group Limited Introduces Avian Influenza A Virus Real-Time PCR Test Kit
March 6, 2023
Virax Biolabs Group Limited Announces Purchase Order to Launch COVID-19 and Influenza A+B Antigen Combo Rapid Tests with Cosmos Health (NASDAQ:COSM)
February 6, 2023
Virax Biolabs Introduces Human Papillomavirus ("HPV") Test Kit
January 3, 2023
COVID-19 Rapid Antigen Test Distributed By Virax Biolabs Receives Emergency Use Authorization in the United States
December 5, 2022
Virax Biolabs Appoints Richard Pallin as the Vice President of In Vitro Diagnostic Sales
November 14, 2022
Virax Biolabs Group Limited Announces $3.8 Million Private Placement
November 3, 2022
Virax Biolabs Introduces RSV-Influenza-COVID Triple Virus Antigen Rapid Test Kit
November 2, 2022
Virax Biolabs Group Limited Announces Initiation of its Virax Immune COVID-19 Analytical Performance Study
October 25, 2022
Virax Biolabs Group Limited Announces Distribution Agreement to Market Monkeypox Virus Real-Time PCR Detection Kit with Cosmos Holdings Inc.
September 21, 2022
Virax Biolabs Introduces Monkeypox Virus Antigen Rapid Test Kit
September 19, 2022
Virax Biolabs Announces NASDAQ Closing Bell Ringing to Celebrate Initial Public Offering
August 15, 2022
Virax Biolabs Introduces Monkeypox and Varicella-Zoster Viruses Real-Time PCR Detection Kit
July 25, 2022
Virax Biolabs Group Limited Completes Initial Public Offering; Shares Begin Trading Today on NASDAQ Capital Market as VRAX
July 20, 2022